Compare CMPX & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPX | QURE |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 927.5M | 1.1B |
| IPO Year | 2020 | 2013 |
| Metric | CMPX | QURE |
|---|---|---|
| Price | $1.91 | $22.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | $14.57 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 10.8M | 1.5M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $126.12 |
| Revenue Next Year | $934.41 | $200.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.61 | $8.73 |
| 52 Week High | $6.88 | $71.50 |
| Indicator | CMPX | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 24.24 | 68.60 |
| Support Level | $1.61 | $22.59 |
| Resistance Level | $3.63 | $25.66 |
| Average True Range (ATR) | 0.38 | 1.47 |
| MACD | -0.26 | 0.53 |
| Stochastic Oscillator | 5.04 | 96.04 |
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.